Abstract:
OBJECTIVE: We assessed the safety and efficacy of a 1 a-day twice daily
rabeprazole-based triple therapy for Helicobacler pylori (H .pylon).
METHODS: H. pylori infected patients as confirmed by a rapid urease test
were enrolled in an outpatient based open-label prospective trial.
Symptomatic H. pylori infected patients were assigned to receive amoxicillin
1000 mg, clarithromycin 500 mg and rabeprazole 20 mg all twice daily for 10
days. No maintenance therapy was given during the follow up period. Patients
were followed up during therapy by telephone calls to assess compliance and
any occurrence of adverse effects. The efficacy endpoint was assessed by
using the 14_C urea breath test (UBT). Occurrence of side effects was also
evaluated. RESULTS: A total of 104 patients were analyzed per intention-to-treat (ITT)
and per-protocol (PP). Eradication rates of 87.5% (ITT) and 93.8% (PP) were
obtained. Therapy was relatively well tolerated with minimal side effects. CONCLUSION: Rabeprazole-based triple therapy is a suitable regimen for
eradication of H. pylori infection.
